Does the media prefer PEN or TMDX?

In the previous week, TransMedics Group had 2 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for TransMedics Group and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.54 beat TransMedics Group's score of 0.97 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive TransMedics Group 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, SNN or TMDX?

Smith & Nephew SNATS has higher revenue and earnings than TransMedics Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 1.99 $625M N/A N/A TransMedics Group $605.49M 5.34 $190.29M $3.89 24.06

Does the media prefer SNN or TMDX?

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than TransMedics Group. MarketBeat recorded 11 mentions for Smith & Nephew SNATS and 10 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.97 beat Smith & Nephew SNATS's score of 0.82 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GMED or TMDX?

In the previous week, TransMedics Group had 3 more articles in the media than Globus Medical. MarketBeat recorded 10 mentions for TransMedics Group and 7 mentions for Globus Medical. TransMedics Group's average media sentiment score of 0.97 beat Globus Medical's score of 0.71 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, TMDX or GKOS?

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 5.34 $190.29M $3.89 24.06 Glaukos $507.44M 21.09 -$187.69M -$3.25 N/A

Does the media refer more to TMDX or GKOS?

In the previous week, Glaukos had 16 more articles in the media than TransMedics Group. MarketBeat recorded 26 mentions for Glaukos and 10 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.97 beat Glaukos' score of 0.89 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 7 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, TMDX or PODD?

Insulet has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 5.34 $190.29M $3.89 24.06 Insulet $2.71B 3.66 $247.10M $5.35 26.74

Does the media refer more to TMDX or PODD?

In the previous week, Insulet had 31 more articles in the media than TransMedics Group. MarketBeat recorded 41 mentions for Insulet and 10 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.97 beat Insulet's score of 0.43 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 12 Very Positive mention(s) 1 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

TransMedics Group (TMDX) Competitors

$93.60 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$93.59 -0.01 (-0.01%)

As of 05:43 PM Eastern

Compare

TMDX vs. PEN, SNN, GMED, GKOS, and PODD

Should you buy TransMedics Group stock or one of its competitors? TransMedics Group's main competitors and comparable companies include Penumbra (PEN), Smith & Nephew SNATS (SNN), Globus Medical (GMED), Glaukos (GKOS), and Insulet (PODD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does TransMedics Group compare to Penumbra?

Penumbra (NYSE:PEN) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Penumbra presently has a consensus target price of $367.07, indicating a potential upside of 13.08%. TransMedics Group has a consensus target price of $124.18, indicating a potential upside of 32.67%. Given TransMedics Group's stronger consensus rating and higher probable upside, analysts plainly believe TransMedics Group is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

TransMedics Group has lower revenue, but higher earnings than Penumbra. TransMedics Group is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.11	$177.69M	$4.07	79.76
TransMedics Group	$605.49M	5.34	$190.29M	$3.89	24.06

In the previous week, TransMedics Group had 2 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for TransMedics Group and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.54 beat TransMedics Group's score of 0.97 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Positive
TransMedics Group	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a net margin of 22.69% compared to Penumbra's net margin of 10.67%. TransMedics Group's return on equity of 15.88% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
TransMedics Group	22.69%	15.88%	5.95%

Penumbra has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

88.9% of Penumbra shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

TransMedics Group beats Penumbra on 10 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than TransMedics Group. MarketBeat recorded 11 mentions for Smith & Nephew SNATS and 10 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.97 beat Smith & Nephew SNATS's score of 0.82 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS currently has a consensus price target of $30.93, indicating a potential upside of 5.87%. TransMedics Group has a consensus price target of $124.18, indicating a potential upside of 32.67%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts plainly believe TransMedics Group is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

TransMedics Group has a net margin of 22.69% compared to Smith & Nephew SNATS's net margin of 0.00%. TransMedics Group's return on equity of 15.88% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
TransMedics Group	22.69%	15.88%	5.95%

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Smith & Nephew SNATS has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

Smith & Nephew SNATS has higher revenue and earnings than TransMedics Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	1.99	$625M	N/A	N/A
TransMedics Group	$605.49M	5.34	$190.29M	$3.89	24.06

Summary

TransMedics Group beats Smith & Nephew SNATS on 11 of the 14 factors compared between the two stocks.

How does TransMedics Group compare to Globus Medical?

Globus Medical (NYSE:GMED) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

Globus Medical currently has a consensus price target of $101.77, indicating a potential upside of 22.42%. TransMedics Group has a consensus price target of $124.18, indicating a potential upside of 32.67%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 18.4% of Globus Medical shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, TransMedics Group had 3 more articles in the media than Globus Medical. MarketBeat recorded 10 mentions for TransMedics Group and 7 mentions for Globus Medical. TransMedics Group's average media sentiment score of 0.97 beat Globus Medical's score of 0.71 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has higher revenue and earnings than TransMedics Group. Globus Medical is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.80	$537.87M	$3.91	21.26
TransMedics Group	$605.49M	5.34	$190.29M	$3.89	24.06

TransMedics Group has a net margin of 22.69% compared to Globus Medical's net margin of 17.02%. TransMedics Group's return on equity of 15.88% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
TransMedics Group	22.69%	15.88%	5.95%

Summary

TransMedics Group beats Globus Medical on 9 of the 17 factors compared between the two stocks.

How does TransMedics Group compare to Glaukos?

TransMedics Group (NASDAQ:TMDX) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	5.34	$190.29M	$3.89	24.06
Glaukos	$507.44M	21.09	-$187.69M	-$3.25	N/A

TransMedics Group currently has a consensus target price of $124.18, indicating a potential upside of 32.67%. Glaukos has a consensus target price of $178.08, indicating a potential downside of 1.87%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

TransMedics Group has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Glaukos had 16 more articles in the media than TransMedics Group. MarketBeat recorded 26 mentions for Glaukos and 10 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.97 beat Glaukos' score of 0.89 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	7 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a net margin of 22.69% compared to Glaukos' net margin of -30.68%. TransMedics Group's return on equity of 15.88% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Glaukos	-30.68%	-6.37%	-4.78%

Summary

TransMedics Group beats Glaukos on 12 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Insulet?

TransMedics Group (NASDAQ:TMDX) and Insulet (NASDAQ:PODD) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

TransMedics Group has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Insulet has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

In the previous week, Insulet had 31 more articles in the media than TransMedics Group. MarketBeat recorded 41 mentions for Insulet and 10 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.97 beat Insulet's score of 0.43 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	12 Very Positive mention(s)	1 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group presently has a consensus price target of $124.18, indicating a potential upside of 32.67%. Insulet has a consensus price target of $195.40, indicating a potential upside of 36.60%. Given Insulet's stronger consensus rating and higher probable upside, analysts clearly believe Insulet is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44

Insulet has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	5.34	$190.29M	$3.89	24.06
Insulet	$2.71B	3.66	$247.10M	$5.35	26.74

TransMedics Group has a net margin of 22.69% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Insulet	12.29%	29.29%	13.31%

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Insulet beats TransMedics Group on 9 of the 16 factors compared between the two stocks.

Get TransMedics Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMDX vs. The Competition

Export

Metric	TransMedics Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.23B	$5.75B	$7.31B	$12.78B
Dividend Yield	N/A	1.75%	2.54%	10.79%
P/E Ratio	47.51	26.17	271.78	24.18
Price / Sales	5.34	79.53	696.74	129.13
Price / Cash	23.83	33.71	28.87	36.86
Price / Book	6.24	6.21	11.34	6.52
Net Income	$190.29M	$149.30M	$3.46B	$347.97M
7 Day Performance	3.21%	0.98%	3.23%	1.57%
1 Month Performance	29.53%	9.22%	8.82%	5.24%
1 Year Performance	-18.59%	7.82%	27.70%	17.87%

TransMedics Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMDX TransMedics Group	4.1817 of 5 stars	$93.60 flat	$124.18 +32.7%	-21.9%	$3.23B	$605.49M	24.06	210
PEN Penumbra	3.4514 of 5 stars	$323.59 -0.5%	$367.07 +13.4%	+22.3%	$12.75B	$1.40B	79.51	4,700	Positive News
SNN Smith & Nephew SNATS	2.8679 of 5 stars	$29.59 +1.1%	$30.93 +4.5%	-21.0%	$12.42B	$6.30B	N/A	16,988	News Coverage Analyst Upgrade
GMED Globus Medical	4.3803 of 5 stars	$84.25 -3.1%	$101.77 +20.8%	+34.5%	$11.32B	$2.94B	21.56	6,000
GKOS Glaukos	1.8312 of 5 stars	$186.51 +0.9%	$178.08 -4.5%	+97.3%	$11.01B	$507.44M	N/A	1,094

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMDX) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransMedics Group (TMDX) Competitors

TMDX vs. PEN, SNN, GMED, GKOS, and PODD

How does TransMedics Group compare to Penumbra?

Summary

How does TransMedics Group compare to Smith & Nephew SNATS?

Summary

How does TransMedics Group compare to Globus Medical?

Summary

How does TransMedics Group compare to Glaukos?

Summary

How does TransMedics Group compare to Insulet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransMedics Group (TMDX) Competitors

TMDX vs. PEN, SNN, GMED, GKOS, and PODD

How does TransMedics Group compare to Penumbra?

Do analysts rate PEN or TMDX?

Which has preferable earnings & valuation, PEN or TMDX?

Does the media prefer PEN or TMDX?

Is PEN or TMDX more profitable?

Which has more volatility and risk, PEN or TMDX?

Do insiders and institutionals believe in PEN or TMDX?

Summary

How does TransMedics Group compare to Smith & Nephew SNATS?

Does the media prefer SNN or TMDX?

Do analysts rate SNN or TMDX?

Is SNN or TMDX more profitable?

Do institutionals & insiders believe in SNN or TMDX?

Which has more risk & volatility, SNN or TMDX?

Which has stronger valuation & earnings, SNN or TMDX?

Summary

How does TransMedics Group compare to Globus Medical?

Which has more risk & volatility, GMED or TMDX?

Do analysts prefer GMED or TMDX?

Do institutionals and insiders believe in GMED or TMDX?

Does the media prefer GMED or TMDX?

Which has stronger earnings & valuation, GMED or TMDX?

Is GMED or TMDX more profitable?

Summary

How does TransMedics Group compare to Glaukos?

Which has preferable earnings & valuation, TMDX or GKOS?

Do analysts prefer TMDX or GKOS?

Which has more risk and volatility, TMDX or GKOS?

Do institutionals & insiders hold more shares of TMDX or GKOS?

Does the media refer more to TMDX or GKOS?

Is TMDX or GKOS more profitable?

Summary

How does TransMedics Group compare to Insulet?

Which has more volatility and risk, TMDX or PODD?

Does the media refer more to TMDX or PODD?

Do analysts prefer TMDX or PODD?

Which has stronger valuation & earnings, TMDX or PODD?

Is TMDX or PODD more profitable?

Do insiders & institutionals hold more shares of TMDX or PODD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools